Assassi et al., 2024 - Google Patents
Systemic sclerosis (scleroderma)Assassi et al., 2024
- Document ID
- 17523448846749574133
- Author
- Assassi S
- Varga J
- Publication year
- Publication venue
- The Rose and Mackay Textbook of Autoimmune Diseases
External Links
Snippet
Systemic sclerosis (SSc), historically called scleroderma, is an autoimmune connective tissue disease with complex and poorly understood pathogenesis. SSc has protean clinical manifestations, follows a chronic and commonly progressive course, and is associated with …
- 206010042953 Systemic sclerosis 0 title abstract description 421
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shah et al. | My approach to the treatment of scleroderma | |
Yang et al. | Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis | |
Ha et al. | Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment | |
Richardson et al. | Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study | |
Mayes et al. | Systemic sclerosis | |
US10011883B2 (en) | Causative agents and diagnostic methods relating to rheumatoid arthritis | |
Gemignani et al. | Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients | |
Halleran et al. | Does Hirschsprung-associated enterocolitis differ in children with and without down syndrome? | |
Plastiras et al. | Determinants of pulmonary arterial hypertension in scleroderma | |
Liu et al. | Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis | |
Didona et al. | The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants | |
Assassi et al. | Systemic Sclerosis (Scleroderma) | |
Stoilov et al. | Therapeutic effect of oral CF101 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II study | |
Ikenouchi et al. | Geriatric nutrition risk index predicts prolonged post-stroke dysphagia in acute ischemic stroke | |
Varga et al. | Scleroderma–Systemic Sclerosis | |
JP4174203B2 (en) | How to determine the susceptibility to bone damage | |
RU2722459C1 (en) | Method for determining progression of joint destruction in a patient suffering rheumatoid arthritis background of 5-year therapy of basic anti-inflammatory drugs or basic anti-inflammatory drugs in combination with genetically engineered biological preparations and / or psychopharmacotherapy and accompanying anxiety-depressive disorder | |
Denton et al. | Raynaud’s Phenomenon and Scleroderma | |
Kapur et al. | Exacerbation of asthma by isotretinoin | |
Man et al. | Systemic Sclerosis | |
Derrett-Smith et al. | Systemic sclerosis: clinical features and management | |
Esmaeili et al. | New insights of anti-depressant therapy in the management of ulcerative colitis (UC) | |
Lambova et al. | Systemic sclerosis | |
Hesselstrand et al. | FRI0496 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSC) Patients Treated with Paquinimod (ABR-215757) | |
Fischer | SYSTEMIC SCLEROSIS |